IMG-008 Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving IMG-008 Growth

• Validated IL-36R Pathway with Proven Clinical and Commercial Potential

The IL-36 pathway has emerged as a key driver of neutrophil-mediated inflammation in GPP and other inflammatory disorders. Clinical validation of IL-36R inhibition has already been established by approved therapies targeting this pathway, significantly reducing scientific and regulatory risk for IMG-008. By targeting a biologically validated mechanism, IMG-008 enters development with a stronger probability of success than first-in-class programs.

• Potential Best-in-Class Pharmacokinetic Profile

A major differentiator for IMG-008 is its engineered long half-life. In preclinical studies, IMG-008 demonstrated more than four-fold longer half-life and more than two-fold higher exposure than a comparator anti-IL-36R antibody. These pharmacokinetic advantages could enable less frequent dosing, improved patient convenience, and potentially superior maintenance of disease control. Such attributes are particularly valuable in chronic inflammatory diseases requiring long-term treatment.

• Opportunity in Generalized Pustular Psoriasis (GPP)

GPP is a rare but severe inflammatory skin disease characterized by recurrent, potentially life-threatening flares. Despite recent therapeutic advances, treatment options remain limited. ImageneBio specifically identified GPP as a lead indication for IMG-008, and the need for therapies capable of both acute flare control and long-term prevention creates a meaningful commercial opportunity. The orphan nature of GPP may also support premium pricing and favorable reimbursement if approved.

• Expansion Potential into Hidradenitis Suppurativa and Other Inflammatory Diseases

Beyond GPP, IMG-008 is being developed for broader inflammatory indications, including hidradenitis suppurativa (HS). HS affects millions of patients worldwide and remains significantly underserved despite recent biologic approvals. The IL-36 pathway has been implicated in HS pathogenesis, providing a scientific rationale for expansion into a substantially larger patient population than GPP alone. Successful proof-of-concept in multiple indications could significantly expand the drug's commercial addressable market.

• Designed for Both Acute Treatment and Long-Term Maintenance

According to company disclosures, IMG-008's enhanced exposure and prolonged half-life were specifically engineered to support not only treatment of acute inflammatory episodes but also prevention of disease recurrence through maintenance therapy. Chronic maintenance treatment generally supports longer treatment duration and higher lifetime patient value compared with therapies used only during acute flares.

• Regulatory Advancement and Pipeline Prioritization

The US FDA granted Investigational New Drug (IND) clearance for IMG-008, allowing initiation of clinical development. ImageneBio has repeatedly highlighted IMG-008 as a core asset within its immunology portfolio and has advanced it into global Phase I development. Continued investment alongside the company's lead immunology programs suggests management sees substantial long-term value in the asset.

IMG-008 Recent Developments

In February 2023, Inmagene Biopharmaceuticals announced that the US Food and Drug Administration (FDA) granted the initial investigational new drug (IND) application for its drug candidate IMG-008, a long-acting anti-IL-36R antibody with enhanced half-life and exposure.

“IMG-008 Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of IMG-008 for potential indication like Generalised pustular psoriasis and Hidradenitis suppurativa in the 7MM. A detailed picture of IMG-008’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the IMG-008 for potential indications. The IMG-008 market report provides insights about IMG-008’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current IMG-008 performance, future market assessments inclusive of the IMG-008 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of IMG-008 sales forecasts, along with factors driving its market.

IMG-008 Drug Summary

IMG-008 is an investigational, orally administered small-molecule therapy developed by Inmagene Biopharmaceuticals that selectively targets tyrosine kinase 2 (TYK2), a member of the Janus kinase family involved in the signaling of key inflammatory cytokines such as interleukin-12 (IL-12), interleukin-23 (IL-23), and type I interferons. Designed to provide potent immunomodulatory activity with improved selectivity over broader JAK inhibitors, IMG-008 aims to suppress pathogenic immune responses while minimizing off-target effects. The drug is being investigated for the treatment of several autoimmune and inflammatory disorders, including Alopecia Areata and other immune-mediated diseases. Preclinical and early clinical studies have demonstrated favorable pharmacokinetic properties, selective TYK2 inhibition, and the potential to reduce inflammation through modulation of multiple cytokine pathways, positioning IMG-008 as a promising next-generation oral therapy in the evolving autoimmune disease treatment landscape. The report provides IMG-008’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the IMG-008 Market Report

The report provides insights into:

• A comprehensive product overview including the IMG-008 MoA, description, dosage and administration, research and development activities in potential indication like Generalised pustular psoriasis and Hidradenitis suppurativa.
• Elaborated details on IMG-008 regulatory milestones and other development activities have been provided in IMG-008 market report.
• The report also highlights IMG-008‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The IMG-008 market report also covers the patents information, generic entry and impact on cost cut.
• The IMG-008 market report contains current and forecasted IMG-008 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The IMG-008 market report also features the SWOT analysis with analyst views for IMG-008 in potential indications.

Methodology

The IMG-008 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IMG-008 Analytical Perspective

• In-depth IMG-008 Market Assessment

This IMG-008 sales market forecast report provides a detailed market assessment of IMG-008 for potential indication like Generalised pustular psoriasis and Hidradenitis suppurativa in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted IMG-008 sales data uptil 2034.

• IMG-008 Clinical Assessment

The IMG-008 market report provides the clinical trials information of IMG-008 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

IMG-008 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

IMG-008 Market Potential & Revenue Forecast

• Projected market size for the IMG-008 and its key indications
• Estimated IMG-008 sales potential (IMG-008 peak sales forecasts)
• IMG-008 Pricing strategies and reimbursement landscape

IMG-008 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• IMG-008 Market positioning compared to existing treatments
• IMG-008 Strengths & weaknesses relative to competitors

IMG-008 Regulatory & Commercial Milestones

• IMG-008 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

IMG-008 Clinical Differentiation

• IMG-008 Efficacy & safety advantages over existing drugs
• IMG-008 Unique selling points

IMG-008 Market Report Highlights

• In the coming years, the IMG-008 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The IMG-008 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IMG-008’s dominance.
• Other emerging products for Generalised pustular psoriasis and Hidradenitis suppurativa are expected to give tough market competition to IMG-008 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IMG-008 in potential indications.
• Analyse IMG-008 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted IMG-008 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of IMG-008 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of IMG-008? How strong is IMG-008’s clinical and commercial performance?
• What is IMG-008’s clinical trial status in each individual indications such as Generalised pustular psoriasis and Hidradenitis suppurativa and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IMG-008 Manufacturers?
• What are the key designations that have been granted to IMG-008 for potential indications? How are they going to impact IMG-008’s penetration in various geographies?
• What is the current and forecasted IMG-008 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of IMG-008 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to IMG-008 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is IMG-008? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.